Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis
- PMID: 15448128
- DOI: 10.1093/jac/dkh430
Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis
Abstract
Objectives: To evaluate whether an engineered synthetic decapeptide (KP) derived from the sequence of a recombinant anti-idiotypic antibody, that represents the internal image of a Pichia anomala killer toxin, could be fungicidal in vitro and therapeutic in vivo against Paracoccidioides brasiliensis and paracoccidioidomycosis (PCM).
Methods: Fungicidal activity of KP was assessed in vitro and in vivo by inhibition of colony forming units and by histological examination, 8 days after infection, of organs from mice intravenously injected with a virulent strain of P. brasiliensis (3 x 10(6) yeast cells) and intraperitoneally treated with KP (3.3 microg/g body weight, three doses), in comparison with control animals equally administered with a scrambled decapeptide (SP).
Results: KP but not SP was fungicidal in vitro at 39 ng/multiply-budding yeast cell and less efficiently in its D-isomeric form (0.31 microg/multiply-budding yeast cell). It was also able to markedly reduce the fungal load in organs (liver, lung, spleen) of infected animals.
Conclusions: The therapeutic effect observed opens the way for using the antifungal peptide as an alternative control of PCM in association with conventional antifungal drugs.
Similar articles
-
Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29. Antimicrob Agents Chemother. 2008. PMID: 18824612 Free PMC article.
-
In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide.J Antimicrob Chemother. 2006 May;57(5):891-8. doi: 10.1093/jac/dkl051. Epub 2006 Feb 28. J Antimicrob Chemother. 2006. PMID: 16507561
-
From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.Antonie Van Leeuwenhoek. 2011 Jan;99(1):35-41. doi: 10.1007/s10482-010-9496-3. Epub 2010 Aug 18. Antonie Van Leeuwenhoek. 2011. PMID: 20714805
-
Killer anti-idiotypes in the control of fungal infections.Curr Opin Investig Drugs. 2001 Apr;2(4):477-9. Curr Opin Investig Drugs. 2001. PMID: 11566002 Review.
-
From yeast killer toxins to antibiobodies and beyond.FEMS Microbiol Lett. 2008 Nov;288(1):1-8. doi: 10.1111/j.1574-6968.2008.01340.x. FEMS Microbiol Lett. 2008. PMID: 18785931 Review.
Cited by
-
Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system.Appl Environ Microbiol. 2005 Oct;71(10):6360-7. doi: 10.1128/AEM.71.10.6360-6367.2005. Appl Environ Microbiol. 2005. PMID: 16204558 Free PMC article.
-
Antibody Peptide based antifungal immunotherapy.Front Microbiol. 2012 Jun 1;3:190. doi: 10.3389/fmicb.2012.00190. eCollection 2012. Front Microbiol. 2012. PMID: 22675322 Free PMC article.
-
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?J Fungi (Basel). 2020 Nov 19;6(4):300. doi: 10.3390/jof6040300. J Fungi (Basel). 2020. PMID: 33228010 Free PMC article. Review.
-
Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29. Antimicrob Agents Chemother. 2008. PMID: 18824612 Free PMC article.
-
Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.PLoS One. 2008 Jun 11;3(6):e2371. doi: 10.1371/journal.pone.0002371. PLoS One. 2008. PMID: 18545659 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources